HANSOH PHARMA lowers CB conversion price to HK$56.54, potential share issuance up 1.5%

Bulletin Express
08/26

Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA) will adjust the conversion price of its HK$4.68 billion zero-coupon convertible bonds (due 2033) following the interim dividend record date for the six months ended 30 June 2026.

• Conversion price: reduced from HK$57.39 to HK$56.54 per share, effective 28 September 2026.

• Dilution impact: maximum shares issuable on full conversion increases from 81.55 million to 82.77 million, an additional 1.23 million shares (+1.50%).

• Bond size unchanged: outstanding principal remains HK$4.68 billion; all other bond terms are unaffected.

The adjustment complies with the terms of the convertible bonds, reflecting the dividend-related reset mechanism. Chairlady Zhong Huijuan signed the announcement on 26 August 2026.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10